ASCO Breast Cancer Video Recap

Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer

June 07, 2017

Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

June 06, 2017

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer

June 06, 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline BRCA 1/2 mutations during the 2017 ASCO Annual Meeting.

Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast Cancer

June 06, 2017

Sara M. Tolaney, MD, MPH, associate director, clinical research, breast oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, discusses interim results of a trial exploring abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive HER2-negative breast cancer.

Results of the APHINITY Trial in HER2-Positive Breast Cancer

June 06, 2017

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the APHINITY trial, which compared chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.